US biotechnology company Windtree Therapeutics, Inc. (NASDAQ: WINT) has announced the receipt of a patent approval in Hong Kong for its drug istaroxime. The patent, titled “Istaroxime-containing intravenous formulation for the treatment of heart failure (AHF),” covers formulations comprising istaroxime and methods of use, either alone or in combination with other agents for the treatment and management of AHF. This patent, valid until 2039, complements the one granted in mainland China earlier this year (patent number ZL201980003356.1).
History and Development of Istaroxime
Istaroxime, originally discovered by Italy-based Sigma-Tau (now Leadiant Biosciences), was sold to Taiwan’s CVie Therapeutics in 2012. CVie later merged with Windtree in 2018. The molecule functions as a positive inotropic agent, increasing myocardial contractility through a dual mechanism: inhibiting Na+/K+- ATPase while activating the SERCA2a calcium pump, which enhances calcium reuptake from the cytoplasm.
Lee’s Pharmaceutical Ltd’s Licensing Deal with Windtree
China-based Lee’s Pharmaceutical Ltd (HKG: 0950) invested USD 138 million to license the drug istaroxime and rostafuroxin from Windtree for Greater China in January this year, highlighting the drug’s potential impact on the regional market.- Flcube.com
